Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

View Full Paper
Ask AI
Bookmark
Share

Authors

VGVikas A. GuptaANAjay K. Nooka

Discussion

Loading...

Member takes

Overview

Cohort analysis identified 143 NDMM patients achieving long-term progression-free survival, suggesting autologous stem cell transplantation may enhance outcomes.

Key Points

  • Long-term progression-free survival reached 10 years in 143 patients, indicating promising clinical features.
  • Among the 836 eligible patients, younger age correlated with a higher rate of prolonged progression-free survival.
  • Cohort analysis primarily utilized patient data treated with lenalidomide, bortezomib, and dexamethasone.
  • Higher rates of maintenance therapy and lower hemoglobin at diagnosis were linked to reduced long-term survival.

Cite This Study

Gupta et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7fchttps://doi.org/10.1182/blood-2025-2812
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression2025
  2. 2Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.2025
  3. 3Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study2025
  4. 4Real-world study on discontinuation strategies after MRD negativity in multiple myeloma patients2025
  5. 5Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025